Peptigrade

Immune Modulation & Geroprotection

Thymalin

Thymalin — bovine thymus polypeptide complex (mixture of short immunomodulatory peptides including Glu-Trp (EW), Lys-Glu (KE), and EDP)·Also known as: Тималин, Thymalinum, Thymarin, Thymic polypeptide complex (calf thymus), Khavinson thymic extract

FDARegulatory status

Not approved for human use in the United States. Thymalin has never been filed with FDA for any indication; no IND is on record in the Drugs@FDA registry, and no Phase 1, Phase 2, or Phase 3 trial under FDA oversight has ever been registered on ClinicalTrials.gov. The compound is sold in the U.S. only as a research chemical for in-vitro and animal study. It is not in FDA 503A Category 1 on the April 15, 2026 Categories Update and is therefore not a compoundable human drug substance under Section 503A.

WADARegulatory status

Not individually named on the 2026 WADA Prohibited List. As a non-approved (outside the former USSR / Russian Federation) peptide mixture with immunomodulatory claims, it is captured by S0 — Non-Approved Substances — on the 2026 list in force January 1, 2026. Athletes under WADA jurisdiction should treat it as prohibited absent specific TUE guidance.

Regulatory note ·Thymalin is a registered pharmaceutical in the Russian Federation (originally registered in the USSR in 1982 under the Ministry of Health of the USSR and continuously marketed in the Russian Federation thereafter by Samson-Med, St. Petersburg). The approved indications are adjunctive treatment of immunodeficiency, chronic infection, post-surgical immune suppression, and select immune-mediated dermatologic and oncologic supportive-care settings. Unlike most entries in the Peptigrade database, Thymalin is NOT a defined single-molecule peptide — it is a polypeptide mixture extracted from calf thymus by mild acid hydrolysis and released to spec by total peptide content and HPLC fingerprint rather than by a single-component assay. This mixture-versus-single-molecule distinction has major regulatory and evidentiary consequences: it is one reason Thymalin has never been filed with FDA or EMA as a biologic-defined drug, and it complicates head-to-head comparison with synthetic immunomodulatory peptides. The efficacy literature is dominated by the originating Khavinson laboratory at the St. Petersburg Institute of Bioregulation and Gerontology and by closely affiliated Russian clinical groups; independent Western replication is essentially absent. Under the Peptigrade source hierarchy, single-lab / single-national-program evidence caps efficacy grades at C regardless of reported effect size.

§ The quick take

TL;DR · Editor’s summary

Thymalin is an unusual entry in the Peptigrade database and the caveats should be read before any clinical weight is placed on the grades. First, it is not a single peptide — it is a polypeptide mixture extracted from calf thymus by mild acid hydrolysis, with the dipeptide Glu-Trp (EW), the dipeptide Lys-Glu (KE), and a poorly-characterized tripeptide (EDP) identified as the leading candidate active components. Batch identity is verified by HPLC fingerprint and total peptide content, not by a single-molecule assay, which has significant implications for batch-to-batch consistency and for regulatory review outside the originating jurisdiction. Second, Thymalin is a registered pharmaceutical in the Russian Federation (originally registered in the USSR in 1982, continuously marketed since) indicated for adjunctive immune reconstitution in secondary immunodeficiency, chronic infection, post-surgical immune suppression, and select supportive-care settings — it has never been filed with FDA, EMA, MHRA, Health Canada, TGA, or PMDA.

Third, the published efficacy literature is dominated by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, the Kuznik group, and closely affiliated Russian clinical centers; independent Western replication is essentially absent. The most recognizable contemporary trial — Kuznik et al. 2021 in Frontiers in Pharmacology — is an open-label, non-randomized comparative study in 110 hospitalized elderly COVID-19 patients that reported approximately halved hospital mortality (15.9% vs 35.2%) and faster immunologic recovery in the Thymalin arm. The effect size is striking but the design (no placebo, non-randomized allocation, single national program, pandemic-era confounding) keeps the grade at C.

Geroprotection cohorts (Khavinson & Morozov 2003 and related 6–8 year follow-ups) report reduced respiratory infection frequency and reduced all-cause mortality in institutionalized elderly subjects, but most of this work combines Thymalin with the pineal peptide Epithalamin, limiting attribution. Mechanistic work characterizing EW, KE, and EDP as sequence-selective DNA-binding short peptides that modulate gene expression is distinctive and has English-language publications, but Western molecular-biology replication remains limited. Safety signals from Russian post-marketing use are reassuring across four decades, but are single-source. Under the Peptigrade rubric single-lab / single-national-program evidence caps grades at C, and the mixture-versus-defined-molecule status is an additional ceiling that would need to be addressed by a CMC-quality characterization program before any Western registration pathway is plausible.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Thymalin, sorted by strength of evidence.

C

Adjunctive immunomodulation in severe COVID-19 in older adults

Mixed

Kuznik (2021, Frontiers in Pharmacology) reported a prospective two-center comparative study in hospitalized COVID-19 patients aged 60+ (n=110; Thymalin + standard therapy vs standard therapy alone): hospital mortality approximately halved in the Thymalin arm (15.9% vs 35.2%), faster reversal of lymphopenia, and more rapid recovery of CD3+HLA-DR+, CD4+, B-cell, and NK-cell subpopulations. Open-label, non-randomized, single-group-of-institutions, and conducted under pandemic conditions — the effect size is large but the trial design does not clear the B threshold under the Peptigrade rubric.

3 studiesUpdated 2026-04-20
C

Geroprotection & reduction of all-cause mortality in elderly cohorts

Mixed

Khavinson & Morozov (2003, Neuroendocrinology Letters) and subsequent Khavinson group publications reported 6–8 year follow-up cohorts in institutionalized elderly subjects showing reduced respiratory infection frequency, improved immunologic indices, and reduced all-cause mortality with periodic Thymalin courses (often combined with the pineal peptide Epithalamin). Cohorts are not randomized or blinded, originate from a single research program, and the combined-intervention design (Thymalin + Epithalamin) limits attribution to Thymalin alone.

4 studiesUpdated 2026-04-20
C

T-cell maturation & restoration of CD4+/CD8+ subsets in secondary immunodeficiency

Mixed

Kuznik (2020, Acta Naturae) reviewed decades of Russian clinical data showing Thymalin-induced increases in CD3+, CD4+, and activated HLA-DR+ T-cell populations and normalization of CD4/CD8 ratio in patients with post-surgical, post-infection, and age-related secondary immunodeficiency. Mechanistic consistency across studies is strong; study-level design is open-label clinical-series grade.

12 studiesUpdated 2026-04-20
C

Short-peptide regulation of gene expression (epigenetic / cytomedin mechanism)

Mixed

Khavinson (2011, 2020) and the Institute of Bioregulation and Gerontology group have documented that the active short peptides (EW, KE, EDP) bind double-stranded DNA in a sequence-selective manner and modulate expression of immune and gerontogene-class genes in cultured lymphocytes and fibroblasts. The 'peptide bioregulator' / cytomedin framework is distinctive and has English-language publications; independent replication in Western molecular-biology groups remains limited.

8 studiesUpdated 2026-04-20
D

Adjunct in chronic infection & post-surgical immune suppression

Weak

Registered Russian indication with decades of clinical use. Published evidence is predominantly Russian-language open-label series and monographs; English-language peer-reviewed trial data is thin. Mechanistic plausibility is consistent with the T-cell-restoration body of work, but the specific-indication evidence base is below the threshold for C.

6 studiesUpdated 2026-04-20
D

Oncology supportive care (chemotherapy-associated immunosuppression)

Weak

Russian oncology centers have used Thymalin as supportive care during chemotherapy for immune reconstitution. Published evidence is small, open-label, and non-randomized. No Western oncology-supportive-care trial.

4 studiesUpdated 2026-04-20
Ins.

Immune enhancement in healthy adults (off-label anti-aging use)

Insufficient

Frequent online claim. No controlled trial in healthy adults has been published. The geroprotection cohort work is in institutionalized elderly subjects with baseline immunosenescence and is not generalizable to healthy users seeking immune-boosting effects.

1 studiesUpdated 2026-04-20

§ Why this grade

Sub-scores for this outcome.

Adjunctive immunomodulation in severe COVID-19 in older adults

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

3 / 5

T-cell-maturation framework (Morozov & Khavinson 1991; Kuznik 2020 review) and cytomedin DNA-binding hypothesis (Khavinson 2011, 2020) are characterized at pathway and cell-population level. No defined single receptor because Thymalin is not a single molecule. Human PK for the intramuscular formulation is not published in Western literature. Cytokine rebalancing (Th1-shift, IL-6 reduction) is internally consistent across the Kuznik group's reports. Partial score reflects functional-and-population-level mechanism without molecular-structural confirmation outside the originating program.

Human studies (count + quality)

2 / 5

Kuznik 2021 open-label comparative study (n=110, hospitalized COVID-19 patients 60+) is the pivotal contemporary trial — no randomization, no placebo, single group of Russian institutions. Prior immunodeficiency literature is decades of open-label clinical series. Under the Peptigrade source hierarchy this is tier-5 (open-label / pilot) evidence — C-band at best regardless of reported effect size.

Effect vs placebo

2 / 5

No placebo-controlled trial exists. Kuznik 2021 uses standard-therapy-alone as comparator rather than placebo, with non-randomized allocation. The reported approximately 50% mortality reduction (15.9% vs 35.2%) is large but the expectancy/allocation/era-of-care confounders cannot be separated without a randomized placebo-controlled design. A B-grade requires placebo-controlled human data this program has not produced.

Long-term safety data

3 / 5

Registered in the USSR/Russia since 1982 — over four decades of post-marketing use across the Russian Federation. Russian clinical literature consistently reports benign adverse-effect profile. Formal long-term cohort data in Western peer-reviewed literature is absent. Bovine-extract origin and mixture-versus-defined-molecule status raise questions (prion, zoonotic pathogen, batch variability, anti-drug antibody formation) that Russian practice manages but that have not been independently audited at Western regulatory depth.

Side effect profile

4 / 5

Russian clinical reports across four decades consistently describe a benign adverse-effect profile: occasional local injection-site reaction, rare hypersensitivity; no hepatotoxicity, no hematologic toxicity at standard courses. Score held at 4 rather than 5 because the entire safety narrative is single-national-program and lacks independent post-marketing surveillance and modern immunogenicity characterization for a bovine-derived peptide mixture.

Regulatory status

2 / 5

Registered in the Russian Federation (originally USSR 1982) as an adjunctive immunomodulator. Not FDA-approved, not EMA-approved, not approved in the UK, Canada, Australia, or Japan. WADA S0 applies by default. Regulatory recognition is real and long-standing but jurisdiction-limited and not convertible to Western prescribing. Mixture-versus-single-molecule status is an additional barrier to any Western registration pathway.

§ What the science says

How Thymalin
works.

The scientific explanation of the molecule and its proposed mechanism, with a plain-English translation — written at an 8th-grade reading level — in the teal callouts below each section. Every claim is linked to a primary source below.

What it is

Thymalin is a polypeptide complex isolated from calf thymus tissue by mild acid extraction and ultrafiltration, supplied as a lyophilized powder for reconstitution and intramuscular injection (the registered Russian formulation is 10 mg vials). Developmental work at the Military Medical Academy (Kirov) in Leningrad under V.G. Morozov and V.Kh. Khavinson in the late 1970s led to initial USSR Ministry of Health registration in 1982. The extract contains short peptides of approximately 1–10 amino acids; the identified active components include the dipeptide Glu-Trp (EW, molecular formula C₁₆H₁₉N₃O₅, MW approximately 333.3 Da), the dipeptide Lys-Glu (KE, marketed separately as the synthetic cytomedin Vilon), and a tripeptide referred to as EDP. The Glu-Trp dipeptide has been independently developed as the synthetic cytomedin Thymogen, which is sometimes described as 'synthetic Thymalin' although the two products are regulated separately and have non-identical dossiers. Thymalin is the reference polypeptide-mixture entry in the Khavinson 'peptide bioregulator' (cytomedin) framework — the theoretical system under which short thymic, pineal, and organ-derived peptides are proposed to bind genomic DNA in a sequence-selective manner and regulate tissue-specific gene expression.

In plain English

Thymalin is a mixture of short peptides extracted from calf thymus tissue. It is sold as a freeze-dried powder for injection into muscle (10 mg vials, the standard Russian formulation). It was developed in Leningrad (now St. Petersburg) in the late 1970s under researchers V.G. Morozov and V.Kh. Khavinson, and was approved in the Soviet Union in 1982. The thymus is a gland near the heart that trains and matures T-cells — the immune system's precision fighters. As people age, the thymus shrinks and T-cell production slows. The idea behind thymalin is to restore that thymic signal from outside the body. The active components identified in the extract are two dipeptides — Glu-Trp (EW, also developed separately as the synthetic drug Thymogen) and Lys-Glu (KE, also known as Vilon) — plus a tripeptide called EDP. Thymalin is not a single purified chemical: it is the whole extract, verified by a lab fingerprint of multiple components, not by one defined compound. The theoretical framework behind it — called the cytomedin or peptide bioregulator model — proposes that these short peptides can enter cell nuclei and tune gene activity directly.

How it works

  1. 01

    T-cell maturation and CD4+/CD8+ restoration

    Kuznik (2020, Acta Naturae) consolidates the long-running Russian clinical body of work showing that Thymalin administration to patients with secondary immunodeficiency drives measurable increases in CD3+ total T-cells, CD4+ helper T-cells, and activated CD3+HLA-DR+ cells, with normalization of the CD4/CD8 ratio. The proposed mechanism is thymic-peptide replacement driving maturation of progenitor T-cells in involuting or partially functional thymic tissue — a framework originally proposed by Morozov & Khavinson (1991) and developed across subsequent decades. The mechanism is consistent across indications (post-surgical, post-infection, geriatric immunodeficiency) but is characterized almost entirely within Russian clinical and preclinical programs.

    In plain English

    It may help the immune system rebuild its T-cell defenses

    The core idea: as people age or get sick, the thymus gland shrinks and makes fewer T-cells. Thymalin contains peptides from calf thymus that may signal immature T-cell precursors to grow up and specialize. Russian clinical data consistently show rises in total T-cells, helper T-cells, and activated T-cells after thymalin treatment in people with weakened immunity. The pattern holds across post-surgical, post-infection, and age-related immune decline. But the entire mechanistic story comes from one research program in Russia.

  2. 02

    Short-peptide DNA binding and gene-expression modulation (cytomedin mechanism)

    Khavinson (2011, Bulletin of Experimental Biology and Medicine) and Khavinson (2020, Biogerontology) propose that the active short peptides in Thymalin (EW, KE, EDP) enter the cell nucleus and bind double-stranded DNA in a sequence-selective manner, interacting with promoter regions of immune and 'gerontogene' class genes. In cultured lymphocytes and fibroblasts the group has reported altered expression of interleukin, interferon, and cell-cycle genes following Thymalin or single-peptide exposure. This is the theoretical core of the 'peptide bioregulator' framework. English-language publications exist, but independent Western molecular-biology replication of the sequence-selective DNA-binding claims is limited and the mechanism remains controversial outside the originating program.

    In plain English

    The active peptides may change which genes are switched on

    Khavinson and colleagues have published evidence that the short peptides in thymalin (EW, KE, EDP) can enter the cell nucleus and bind directly to DNA in a sequence-specific way. The theory: binding specific gene-promoter regions turns immune genes and 'aging genes' on or off. This is the core claim of the cytomedin (peptide bioregulator) framework and has some English-language publications. Independent Western molecular biology labs have not confirmed the DNA-binding claim, so it remains controversial outside the originating research program.

  3. 03

    Cytokine rebalancing (Th1 / Th2, IL-6, TNF-α)

    Across the Kuznik group's clinical reports, Thymalin administration in immunodeficient and COVID-19 cohorts is accompanied by a shift toward Th1-dominant cytokine signaling (increased IFN-γ, IL-2) and reduction of elevated IL-6 and TNF-α where baseline levels are pathologically elevated. In healthy-control cohorts cytokine parameters move less, framed as 'adaptogenic' normalization rather than generalized immune stimulation. The pattern is internally consistent across reports from the originating program but is not independently replicated in Western immunology literature.

    In plain English

    It may shift the immune response away from runaway inflammation

    In the COVID-19 and immunodeficiency studies, thymalin treatment was associated with a shift toward a Th1-type immune response — more interferon-gamma and IL-2 (the precision-attack signals) — and lower IL-6 and TNF-alpha when those were abnormally elevated (the runaway-inflammation signals). In people with normal immune function, changes were smaller — framed as normalizing rather than simply boosting. All of this data comes from the Kuznik/Khavinson group and has not been independently reproduced.

  4. 04

    NK-cell and B-cell subpopulation effects

    The Kuznik (2021) COVID-19 study quantified recovery of NK-cell and B-cell subpopulations alongside T-cell compartments in the Thymalin arm relative to standard-therapy control. Earlier Russian work had documented similar NK-cell enhancement in post-surgical and oncology supportive-care contexts. The breadth of immune-compartment effects is one reason Thymalin is described as a general immune-reconstitution agent rather than a T-cell-specific one, though the mechanistic basis for effects on NK and B compartments is less developed than for T-cells.

    In plain English

    It also appears to help restore other immune cell types

    The 2021 COVID-19 trial tracked not just T-cells but also natural killer (NK) cells and B-cells (which make antibodies). Both populations recovered faster in the thymalin group. Earlier Russian work in surgical and cancer patients reported similar NK-cell increases. This suggests thymalin's effect is broader than T-cells alone. The mechanism for how it affects NK and B cells is less worked out than the T-cell story.

  5. 05

    Geroprotection and interaction with the pineal peptide Epithalamin

    Khavinson & Morozov (2003, Neuroendocrinology Letters) reported a 6–8 year follow-up of institutionalized elderly subjects in which periodic courses of Thymalin (alone or combined with the pineal peptide Epithalamin) were associated with reduced respiratory infection frequency, improved immunologic indices, and reduced all-cause mortality. The proposed mechanism is combined restoration of thymic and pineal 'bioregulator' signaling in age-related endocrine involution. This is the most-cited geroprotection evidence for Thymalin, but the combined-intervention design limits causal attribution to Thymalin alone, and the cohorts are non-randomized.

    In plain English

    Long-term use may slow immune aging — but the data mixes two drugs

    The 6–8 year nursing-home cohorts (Khavinson & Morozov 2003) gave residents periodic thymalin courses, usually combined with Epithalamin (a pineal-gland extract). The theory: aging causes both thymic and pineal signals to decline, and restoring both together works better than either alone. The results — fewer respiratory infections, better immune readings, lower death rates — are striking. The problem is that thymalin and Epithalamin were almost always given together, so you can't tell which drug drove which effect.

  6. 06

    What is NOT known about the mechanism

    No defined single-molecule receptor has been identified for Thymalin because Thymalin is not a single molecule. The sequence-selective DNA-binding claims for EW, KE, and EDP are mechanistically important to the cytomedin framework but have not been confirmed at cryo-EM or high-resolution structural detail by an independent group. Human pharmacokinetics for the registered intramuscular formulation are not characterized in the English-language peer-reviewed literature. The relative contribution of EW, KE, EDP, and other uncharacterized peptides in the extract to the clinical effect is not dissected — most clinical trials test the mixture, not the purified components. Batch-to-batch identity of a biological extract is inherently harder to establish than for a synthetic single-molecule peptide and has not been addressed at Western-regulatory CMC depth.

    In plain English

    What we still don't understand

    Thymalin has no single identified receptor because it is not a single molecule. The DNA-binding claims for the active peptides have not been confirmed at high structural resolution (cryo-EM, X-ray crystallography) by any independent group. Human pharmacokinetics — how fast it is absorbed, how long it stays in the body, where it goes — are not published in English-language peer-reviewed journals. The relative contribution of each peptide in the extract (EW, KE, EDP, and possibly others) has not been separated — clinical trials test the mixture, not each component alone. Verifying batch-to-batch identity for a biological extract is inherently harder than for a synthetic single molecule, and that verification has not been reviewed to Western regulatory standards.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Adjunctive treatment of severe COVID-19 in older adults

    Kuznik 2021 open-label comparative study (n=110); ~50% reduction in hospital mortality reported. No randomized Western replication.

  • Secondary immunodeficiency (post-surgical, post-infection, age-related)

    Registered Russian indication since 1982; Kuznik 2020 reviews decades of open-label clinical data.

  • Geroprotection and reduction of elderly all-cause mortality

    Khavinson & Morozov 2003 6–8 year cohort; combined-intervention design with Epithalamin limits attribution.

  • Chronic infection (viral, bacterial, mycobacterial supportive care)

    Registered Russian indication; open-label series only.

  • Oncology supportive care (chemotherapy-associated immunosuppression)

    Russian oncology centers' clinical use; small non-randomized series.

  • Dermatologic immune-mediated conditions (psoriasis, atopic dermatitis — adjunctive)

    Reported in Russian dermatology literature as adjunctive; insufficient for any Western efficacy claim.

  • Cytomedin mechanism research (DNA-binding short peptides, gene regulation)

    Khavinson 2011, 2020 and successors — the theoretical core of the peptide-bioregulator framework.

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    No double-blind, placebo-controlled RCT has been published for any Thymalin indication in a Western peer-reviewed journal. The Russian registration rests on decades of open-label clinical series and the Kuznik 2021 COVID-19 study is open-label and non-randomized. Independent-lab Western replication is the central gap.

  • !

    Thymalin is a polypeptide mixture, not a single molecule. The identity and proportion of the active components (EW, KE, EDP, and any uncharacterized peptides) vary with extraction batch. CMC-quality characterization at Western-regulatory depth has not been published, which is one reason no FDA or EMA filing has ever been made.

  • !

    Human pharmacokinetics for the registered intramuscular formulation — Cmax, Tmax, half-life, tissue distribution, clearance — are not characterized in English-language peer-reviewed literature for the mixture OR for the identified single-peptide components administered alone.

  • !

    The sequence-selective DNA-binding claims that underpin the cytomedin mechanism (Khavinson 2011, 2020) have not been confirmed by independent structural biology groups at cryo-EM, NMR, or X-ray crystallography resolution. Western molecular-biology replication is limited.

  • !

    The geroprotection cohorts (Khavinson & Morozov 2003) combine Thymalin with the pineal peptide Epithalamin, making it impossible to attribute the observed mortality and morbidity effects to Thymalin alone. A Thymalin-monotherapy elderly-cohort trial of comparable duration has not been published.

  • !

    Long-term safety beyond the Russian post-marketing surveillance record is not documented in Western literature. Pregnancy, pediatric, and drug–drug interaction data are absent. Bovine-thymus-extract origin raises theoretical prion and zoonotic-pathogen questions that Russian manufacturing standards address but that have not been independently audited to Western regulatory depth.

  • !

    Immunogenicity (anti-drug antibody formation) with repeated courses of a bovine-derived polypeptide mixture has not been systematically characterized. This is a standard concern for biologic products and especially for undefined mixtures.

  • !

    The relative contribution of the synthetic cytomedin Thymogen (Glu-Trp dipeptide) to Thymalin's clinical effect is not established. If the dominant active species is EW alone, Thymalin's advantage over synthetic Thymogen would need justification — and vice versa.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Thymalinand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Russian peptide bioregulators — Khavinson, Thymalin, and the cytomedin framework

    Huberman Lab·PhD Neurobiology, Stanford

    Walks through the Khavinson lab's cytomedin framework and the distinction between polypeptide mixtures (Thymalin, Epithalamin) and synthetic single-peptide derivatives (Thymogen, Epitalon). Explicit that independent Western replication is limited and that 'registered in Russia' is not equivalent to FDA approval.

    Verified credentials

  • Thymalin in COVID-19 — reading the Kuznik 2021 paper with a methodologist

    Dr. Kyle Gillett·MD, Family Medicine

    Reviews the Kuznik 2021 Frontiers in Pharmacology study in detail. Takes the reported mortality difference seriously while flagging the open-label non-randomized design, single-national-program provenance, and pandemic-era confounding that prevent the result from driving a Western prescribing recommendation on its own.

    Verified credentials

  • Thymalin for anti-aging — my 60-day self-experiment

    Anonymous longevity influencer·Unverified

    First-person anecdotal report from a healthy adult using Thymalin off-label for 'anti-aging' with no objective measure, no product-identity verification, and no follow-up. Misrepresents institutionalized-elderly cohort data as generalizable to healthy adults. Representative of the lower-quality content dominating Thymalin online search results.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 13 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Thymalin in the therapy of severe COVID-19 patients in older age groups: clinical efficacy and possible immunotropic mechanisms

    Kuznik BI, Khavinson VK, Linkova NS, Guts EV, Chalisova NI, Yakovleva SM, Volkov SV, Moroz AN, Trofimova SV · Front Pharmacol · 2021

    Open-labelPMID 34803697
  2. [02]

    The use of Thymalin for immunocorrection and treatment of various pathologies including COVID-19

    Kuznik BI, Khavinson VK, Linkova NS, et al. · Ann Russ Acad Med Sci / PMC · 2021

    Systematic reviewDOI
  3. [03]

    Natural and synthetic thymic peptides as therapeutics for immune dysfunction

    Goldstein AL, Badamchian M · Int J Immunopharmacol · 1998

    Systematic reviewPMID 9637345
  4. [04]

    Peptides and ageing

    Khavinson VK, Morozov VG · Neuro Endocrinol Lett · 2003

    CohortPMID 14523363
  5. [05]

    Peptides and proteins in aging prevention and treatment

    Khavinson VK, Anisimov VN, Linkova NS, Bakhtina MY · Bull Exp Biol Med · 2011

    Systematic reviewPMID 22448342
  6. [06]

    Peptides and aging: molecular mechanisms and therapeutic perspectives

    Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Biogerontology · 2020

    Systematic reviewPMID 32930920
  7. [07]

    Molecular mechanisms of immune regulation by Thymalin and Epithalamin short peptides

    Kuznik BI, Khavinson VK, Linkova NS, et al. · Acta Naturae · 2020

    Systematic reviewPMID 33173602
  8. [08]

    Peptide bioregulators: the new class of geroprotectors. Results of experimental and clinical studies

    Khavinson VK, Morozov VG · Adv Gerontol · 2002

    Systematic reviewPMID 15834840
  9. [09]

    Short peptides: a promising class of geroprotective agents

    Khavinson VK, Anisimov VN · Neuro Endocrinol Lett · 2002

    Systematic reviewPMID 12374005
  10. [10]

    Thymalin — overview, USSR/Russian Federation registration history, and composition

    Wikipedia contributors · Wikipedia · 2026

    RegulatoryLink
  11. [11]

    St. Petersburg Institute of Bioregulation and Gerontology — Thymalin program and peptide bioregulator framework

    St. Petersburg Institute of Bioregulation and Gerontology · gerontology.ru · 2026

    RegulatoryLink
  12. [12]

    WADA 2026 Prohibited List (in force January 1, 2026) — Section S0 Non-Approved Substances

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink
  13. [13]

    FDA 503A Bulk Drug Substances Categories — April 15, 2026 Update (Thymalin not listed in Category 1)

    U.S. Food and Drug Administration · FDA · 2026

    RegulatoryLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

Epitalon

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal polypeptide mixture Epithalamin — the pineal counterpart to Thymalin in the Khavinson cytomedin framework. The geroprotection cohorts that underpin the elderly-mortality claim for Thymalin typically combine Thymalin with Epithalamin, which is Epitalon's parent mixture. Reads the same single-national-program provenance pattern.

Read its grades

Compare

Selank

Russian-developed heptapeptide anxiolytic registered in the Russian Federation. Same evidence-quality pattern (Russian registration, single-national-program literature, no Western RCT replication) and a useful peer for interpreting Russian-literature-based grades.

Read its grades

Compare

Semax

Russian-developed heptapeptide nootropic registered in the Russian Federation. Sister Russian registration story with the same single-national-program evidentiary constraints.

Read its grades

Compare

BPC-157

Different evidence-quality pattern (deep preclinical body, small Western pilots) but the closest peer for thinking about how to grade a peptide with strong mechanistic claims and thin randomized human evidence. Contrast helps calibrate the Thymalin rubric.

Read its grades

Where to research further

Looking for Thymalin
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →